HİLAL NAKKAŞ

Dr. HİLAL NAKKAŞ

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 March 2024 in Journal of Pediatric Urology
Verified
Journal Article
Closed access
TÖTuba Özdemir-Sancı
Tuba Özdemir-Sancı
ASAdem Sancı
Adem Sancı
HNHİLAL NAKKAŞ
HİLAL NAKKAŞ

31 December 2023 in Uludağ Üniversitesi Tıp Fakültesi Dergisi
Verified
Journal Article
Open access
HNHİLAL NAKKAŞ
HİLAL NAKKAŞ
TSTuba Özdemi̇r Sanci
Tuba Özdemi̇r Sanci
BBBEYZA ECEM OZ BEDIR
BEYZA ECEM OZ BEDIR
ETEmine Terzi̇
Emine Terzi̇
Kolorektal kanser (KRK), dünyada en sık görülen üçüncü kanser türüdür. KRK’de ilk tedavi seçeneği cerrahi ve kemoterapidir. Ancak, kullanılan ilaçlara karşı gelişen direnç, uygulanan kemoterapinin başarısız olmasına yol açmaktadır. Son yıllarda yeni teröpatik ajan arayışları, KRK gelişimi ve ilerlemesinde rol oynayan farklı moleküler mekanizmalar üzerinde yoğunlaşmaktadır. mTOR ve MAPK sinyal yolaklarının KRK gelişiminde anahtar rol oynadığı bilinmektedir. Bu çalışmada, KRK hücrelerinde mTOR yolağı inhibitörü Rapamisin (RAPA) ve MAPK yolağı inhibitörü Vemurafenib (VMF)’in apoptoz üzerine olan etkilerinin karşılaştırılması amaçlanmıştır. Çalışmamızda, insan KRK hücrelerinde üretilen HT29 hücre hattı kültüre edilmiştir. RAPA ve VMF’nin HT29 KRK hücreleri üzerindeki uygun dozunun belirlenmesi için WST-1 testi ve apoptotik etkilerinin belirlenmesi amacıyla da akım sitometrisi yöntemi kullanılmıştır. İstatistiksel anlamlılık düzeyi p≤0.05 olarak kabul edilmiştir. Elde ettiğimiz verilere göre, HT29 hücrelerine uygulanacak olan RAPA ve VMF dozu 24. saatte sırasıyla 46,97 μM ve 35,84 μM olarak bulunmuştur. HT29 hücrelerinde RAPA’nın apoptotik süreç üzerinde VMF’den daha etkin olduğu bulunmuştur (RAPA için; p

21 May 2021 in Journal of Health Sciences and Medicine
Verified
Journal Article
Open access
PDF file
ANAndaç Ki̇pAlev Neşeli̇oĞlu
Andaç Ki̇pAlev Neşeli̇oĞlu
GAGülben Akcan
Gülben Akcan
HNHİLAL NAKKAŞ
HİLAL NAKKAŞ
SNsalim neselioglu
salim neselioglu
ÖEÖzcan EREL
Özcan EREL
MÖMeltem Özgüner
Meltem Özgüner
Aim: Methotrexate, a folic acid antagonist, is a chemotherapeutic drug used in the treatment of various inflammatory diseases as well as some cancer types.The purpose of this study; It is the study of the effects of boric acid against the hepatotoxic side effects of methotrexate. Materials and Methods: Male wistar albino rats were divided into five groups of six animals each. The rats in group 1 were used as a control group. Methotrexate was administered to the rats in group 2 and boric acid to the rats in group 3. While the rats in group 4 were given first methotrexate and then boric acid, the rats in group 5 were administered boric acid first and then methotrexate. Results: Light microscopic examination revealed sinusoidal dilatation, hepatocyte degeneration, vascular congestion-thrombosis, and inflammatory infiltration in the livers of rats treated with methotrexate. It was observed that the protective effect of boric acid was more effective than its treatment. In the groups given methotrexate, the level of oxidative stress-related parameters such as lipid hydroperoxide, MPO and disulfide increased (p< 0.05), whereas the level of antioxidant parameters such as native thiol, total thiol and catalase decreased (p< 0.05). Conclusion: In this study, it was determined that the protective effect of boric acid was more than the therapeutic effect in liver damage caused by methotrexate. Oxidative hepatotoxicity resulting from methotrexate application disrupted the thiol disulfide balance and caused it to shift in favor of oxidation.

2 December 2025 in Burns
Verified
Journal Article
Closed access
SAServet Elçin Alpat
Servet Elçin Alpat
BKBurak Kaya
Burak Kaya
HNHİLAL NAKKAŞ
HİLAL NAKKAŞ
PBPınar Bayram
Pınar Bayram
ŞKŞule Kızıl
Şule Kızıl
SGSerdar Mehmet Gültan
Serdar Mehmet Gültan

21 July 2026 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
EAEmre Apaydin
Emre Apaydin
SDSumeyra Doluoglu
Sumeyra Doluoglu
EDElif Dagli
Elif Dagli
SBSevinc Bayrak
Sevinc Bayrak
EKEkrem Said Kankilic
Ekrem Said Kankilic
BCBelgin Can
Belgin Can

30 November 2025 in Eskisehir Medical Journal, Eskisehir City Hospital
Verified
Journal Article
Closed access
HNHİLAL NAKKAŞ
HİLAL NAKKAŞ
ŞKŞeyma Kipel
Şeyma Kipel
Introduction: One kind of testicular cancer which affects germ cells that eventually give rise to sperm is called testicular embryonal carcinoma. These cancer cells can self-renew and differentiate, and they encourage the growth of malignancies. An active byproduct of vitamin A (retinol), retinoic acid (RA), is crucial for both embryonic development and fundamental biological functions such cell division, proliferation, and death. It is frequently utilized as a differentiation inducer in vitro, particularly on cancer and stem cells. S100B protein plays an important role in events such as inflammation, cell growth, cell differentiation, cytoskeleton dynamics and cell movement. NF-κB (nuclear factor kappa B) is a protein complex that is an important transcription factor within the cell. Constantly active NF-κB increases cell proliferation in some cancers and inhibits the immune system's response to the tumor. The aim of the study is to demonstrate how the morphology and S100B and NF-κB expressions of testicular embryonal carcinoma cells change as a result of RA stimulation. Method: After RA was administered to the testicular embryonal carcinoma cells (CRL-2073) at the determined dose (10 μM), crystal violet and luxol fast blue stainings were performed for morphological examination. Then, using immunohistochemical technique, cellular expression and location of S100B and NF-κB in testicular embryonal carcinoma cells were examined. Results: When we stained CRL-2073 cells differentiated with RA with crystal violet, we observed morphological differences in the cell nucleus and cytoplasm, which is a visual indicator of differentiation. Luxol fast blue staining was observed in CRL-2073 cells that began neuronal differentiation with RA. The S100B protein was expressed in embryonal carcinoma cells and was associated with cell differentiation. NF-κB was active in maintaining proliferation and pluripotency in these cells; its activity decreased with differentiation. Conclusion: It is important to show histologically that CRL-2073 cells begin to differentiate with RA. In addition, determining the expression levels of S100B and NF-κB proteins, which are biomarkers for both tumor biology and differentiation processes, by immunostaining before and after RA is a potential treatment target. This information is an important step in understanding cancer biology.